Literature DB >> 11902142

Immunohistochemical localization of phosphorylated AKT in multiple myeloma.

Serhan Alkan, Keith F Izban.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11902142     DOI： 10.1182/blood-2001-01-0317

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

1.  Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer.

Authors:  Gwenny M Fuhler; Robert Brooks; Bonnie Toms; Sonia Iyer; Elizabeth A Gengo; Mi-Young Park; Matthew Gumbleton; Dennis R Viernes; John D Chisholm; William G Kerr
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

2.  In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.

Authors:  Zhijie Li; Fei Tan; David J Liewehr; Seth M Steinberg; Carol J Thiele
Journal:  J Natl Cancer Inst       Date:  2010-05-12       Impact factor: 13.506

3.  Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis.

Authors:  Zhengguang Li; Jun Wu; Changping Wu; Jingting Jiang; Xiao Zheng; Bin Xu; Min Li
Journal:  Oncol Lett       Date:  2012-07-06       Impact factor: 2.967

Review 4.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.

Authors:  Jaclyn LoPiccolo; Gideon M Blumenthal; Wendy B Bernstein; Phillip A Dennis
Journal:  Drug Resist Updat       Date:  2007-12-31       Impact factor: 18.500

5.  Activated Akt as an indicator of prognosis in gastric cancer.

Authors:  Caterina Cinti; Carla Vindigni; Alessandra Zamparelli; Dario La Sala; Maria Carmela Epistolato; Daniele Marrelli; Gabriele Cevenini; Piero Tosi
Journal:  Virchows Arch       Date:  2008-10-08       Impact factor: 4.064

Review 6.  Discovery and development of small molecule SHIP phosphatase modulators.

Authors:  William G Kerr; John D Chisholm; Dennis R Viernes; Lydia B Choi
Journal:  Med Res Rev       Date:  2013-12-02       Impact factor: 12.944

7.  Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies.

Authors:  Jay W Tichelaar; Yu Zhang; Jean C leRiche; Paul W Biddinger; Stephen Lam; Marshall W Anderson
Journal:  BMC Cancer       Date:  2005-12-06       Impact factor: 4.430

8.  A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.

Authors:  J Glauer; N Pletz; M Schön; P Schneider; N Liu; K Ziegelbauer; S Emmert; G G Wulf; M P Schön
Journal:  Blood Cancer J       Date:  2013-09-06       Impact factor: 11.037

Review 9.  The prognostic value of phosphorylated Akt in breast cancer: a systematic review.

Authors:  Zu-Yao Yang; Meng-Yang Di; Jin-Qiu Yuan; Wei-Xi Shen; Da-Yong Zheng; Jin-Zhang Chen; Chen Mao; Jin-Ling Tang
Journal:  Sci Rep       Date:  2015-01-13       Impact factor: 4.379

Review 10.  Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.

Authors:  Jayant S Goda; Tejaswini Pachpor; Trinanjan Basu; Supriya Chopra; Vikram Gota
Journal:  Indian J Med Res       Date:  2016-02       Impact factor: 2.375
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.